Abstract
HM781-36B is a novel and irreversible pan-human epidermal growth factor receptor (HER) inhibitor with TEC cytoplasmic kinase inhibition. The aim of this study is to evaluate the antitumor activity and mechanism of action for HM781-36B in CRC cell lines. The CRC cell lines were exposed to HM781-36B and/or oxaliplatin (L-OHP), 5-fluorouracil (5-FU), SN-38. The cell viability was examined by Cell Titer-Glo luminescent cell viability assay kit. Change in the cell cycle and protein expression was determined by flow cytometry and immunoblot analysis, respectively. Synergism between 2 drugs was evaluated by the combination index. The addition of HM781-36B induced potent growth inhibition in both DiFi cells with EGFR overexpression and SNU-175 cells (IC50, 0.003 µM and 0.005 µM, respectively). Furthermore, HM781-36B induced G1 arrest of the cell cycle and apoptosis, and reduced the levels of HER family and downstream signaling molecules, pERK and pAKT, as well as nonreceptor/cytoplasmic tyrosine kinase, BMX. The combination of HM781-36B with 5-FU, L-OHP, or SN-38 showed an additive or synergistic effect in most CRC cells. These findings suggest the potential roles of HM781-36B as the treatment for EGFR-overexpressing colon cancer, sing...Continue Reading
References
Jan 1, 1984·Advances in Enzyme Regulation·T C Chou, P Talalay
Nov 21, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A McKayH L McLeod
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Apr 12, 2005·The Oncologist·Alan Venook
May 3, 2005·Nature Reviews. Cancer·Nancy E Hynes, Heidi A Lane
Jul 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Todd A CarterDavid J Lockhart
Aug 25, 2005·Clinical Therapeutics·Siu-Fun Wong
Dec 13, 2005·Clinical Colorectal Cancer·Timothy Kuo, George A Fisher
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mace L RothenbergRobert J Coffey
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz-Josef LenzEric K Rowinsky
Mar 17, 2007·ChemMedChem·Yovani Marrero-PonceRichard Rotondo
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Aug 1, 2008·Bioorganic & Medicinal Chemistry Letters·Wooyoung HurNathanael S Gray
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George A FisherBranimir I Sikic
Oct 15, 2009·Anti-cancer Drugs·Helmout Modjtahedi, Sharadah Essapen
Jun 24, 2010·Cancer Research·Manickam JanakiramanDavid B Solit
Aug 26, 2010·The Oncologist·David CameronCharles E Geyer
Feb 11, 2011·Cancer Letters·Hyun-Jin NamYung-Jue Bang
Mar 15, 2011·Journal of the National Cancer Institute·Jeeyun LeeWon Ki Kang
Jul 7, 2011·International Journal of Cancer. Journal International Du Cancer·Mi Young ChaMaeng Sup Kim
Dec 1, 2011·Cancer Science·Arifudin AchmadKeigo Endo
Dec 23, 2011·Molecular Oncology·Rodrigo DienstmannJosep Tabernero
Dec 4, 2012·Recent Patents on Anti-cancer Drug Discovery·John S JarboeChristopher D Willey
Feb 21, 2013·Anti-cancer Drugs·Hye Jin KimYung-Jue Bang
Sep 18, 2013·Oncogenesis·D AhmedR A Lothe
Citations
Sep 26, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xin JinLishan Xu
Aug 14, 2019·PeerJ·Hsueh-Chuan LiuHoong-Chien Lee
Dec 20, 2017·Molecular Medicine Reports·Yufang ZuoZhonghua Yu
Nov 8, 2020·Cancers·Yongchao ZhangDong-Hua Yang